In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Achilles Therapeutics plc

https://achillestx.com

Latest From Achilles Therapeutics plc

IPO Update: What A Difference A (Pandemic) Year Makes

Just nine drug developers went public in the US during the first quarter of last year, but with the industry boosted by pandemic response, 32 biopharma companies launched IPOs in Q1 of this year.

Financing Innovation

Bringing Precision To Solid Tumor Targets

Achilles Therapeutics is betting that its clonal neoantigen-targeting T cell (cNeT) products, combined with an industrial scale advanced manufacturing capability and predictive bioinformatics platform, will have a transformational impact on patients with solid tumors and metastasized cancer.

C-Suite Speaks Business Strategies

30 Rising Leaders In The Life Sciences

Revealed: In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors. Find out who made the cut. 

Business Strategies Commercial

Syncona Biotechs Face Up To Trial Delays Over COVID-19

Clinical trials across the board are being impacted by coronavirus and Syncona, the investment powerhouse behind a number of UK cell and gene therapy biotechs, says that its portfolio companies are facing considerable delays.

Coronavirus COVID-19 Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Pharmacogenetics-Pharmacogenomics
    • Drug Discovery Tools
      • Bioinformatics
UsernamePublicRestriction

Register